Obesity News

In this video, David Nathan, MD, discusses the various treatment options for patients with diabetes.

In a phase 2a trial of patients with obesity-related HF with preserved ejection fraction, a novel controlled metabolic accelerator was associated with weight loss at 3 months compared with placebo.

Prepregnancy bariatric surgery was linked to lower risks for gestational hypertension, large for gestational age infants and gestational diabetes but increased risks for preterm birth and small for gestational age infants, data show.

Decreases in body weight and HbA1c induced by GLP-1 receptor agonists and other diabetes drugs can reduce the risk for cardiometabolic complications for adults newly diagnosed with type 2 diabetes, researchers reported.

A quarter of adults would consider using an injectable weight loss drug without consulting a health care provider, according to the results of a survey from The Ohio State University Wexner Medical Center.

A recently proposed U.S. Senate bill aims to crack down on social media influencers and others online who make misleading comments about pharmaceutical drugs.

Semaglutide was shown to reduce hidradenitis suppurativa flares in patients with obesity, according to a study presented at the European Academy of Dermatology and Venereology meeting.

Women with obesity and atherosclerotic CVD without diabetes experience fewer CV events vs. men enrolled in the SELECT trial; however, semaglutide was linked to significant reductions in CV events regardless of sex, a speaker reported.

Novo Nordisk announced that monlunabant, a novel small molecule oral cannabinoid receptor 1 inverse agonist, was associated with weight loss in a phase 2a study of people with obesity and metabolic syndrome.

BMI in the overweight or obese range for both women and men during preconception or early pregnancy was linked to time to pregnancy success and miscarriage risk, according to study results published in JAMA Network Open.